StreetInsider.com News Articles

Canaccord Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB)

Wed, 26 Aug 2026 06:33:55 -0400

Canaccord analyst Edward Nash reiterated a Buy rating and $7.00 price target on Connect Biopharma Holdings Ltd (NASDAQ: CNTB).

The analyst commented: "Connect is currently conducting its Phase II Seabreeze STAT program with rademikibart for acute respiratory exacerbations (asthma or COPD attacks). Data readout is expected imminently, with Seabreeze STAT asthma expected in the first week of September and Seabreeze STAT COPD expected approximately two weeks later. We wanted to take a moment to review the program and our expectations for the data readout. We reiterate our BUY rating on shares of CNTB and our 12-month, $7 PT."

For an analyst ratings

Form SCHEDULE 13G/A Connect Biopharma Holdin Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26933310.html

Form SCHEDULE 13G/A Connect Biopharma Holdin Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:25:00 -0400

si-local-file:///var/storage/secattach/20260814/26933310.html

Form SCHEDULE 13G/A Connect Biopharma Holdin Filed by: Wei Zheng

Fri, 14 Aug 2026 10:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26926747.html

Form SCHEDULE 13G/A Connect Biopharma Holdin Filed by: Wei Zheng

Fri, 14 Aug 2026 10:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26926747.html

Connect Biopharma (CNTB) Tops Q2 EPS by 189c

Thu, 13 Aug 2026 16:18:00 -0400

Connect Biopharma (NASDAQ: CNTB) reported Q2 EPS of ($0.27), $1.89 better than the analyst estimate of ($2.16). Revenue for the quarter came in at $2.77 million versus the consensus estimate of $226.48 thousand.

For earnings history and earnings-related data on Connect Biopharma (CNTB) click here.

Form 10-Q Connect Biopharma Holdin For: Jun 30

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913156.html

Form 10-Q Connect Biopharma Holdin For: Jun 30

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913156.html

Form 8-K Connect Biopharma Holdin For: Aug 12

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26912998.html

Form 8-K Connect Biopharma Holdin For: Aug 12

Wed, 12 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260812/26912998.html

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD –

– Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 –

– Cash runway expected for a period of at least one year from the date of this release –

SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases,

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 12 Aug 2026 16:05:00 -0400

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD –

– Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 –

– Cash runway expected for a period of at least one year from the date of this release –

Oppenheimer Starts Connect Biopharma Holdings Ltd (CNTB) at Outperform

Thu, 09 Jul 2026 07:47:15 -0400

(Updated - July 9, 2026 7:47 AM EDT)

Oppenheimer initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Outperform rating and a price target of $8.00.

The analyst comments "We are initiating coverage of Connect Biopharma (CNTB) with an Outperform rating and an $8 PT. Connect is developing rademikibart for inflammatory respiratory diseases. A single-asset story, CNTB is built on rademikibart (formerly CBP-201), a next-generation human IgG4 anti-IL-4Rα antibody that binds with higher affinity than dupilumab and, uniquely in the class, drives receptor-independent bronchodilation via pHSP20, producing FEV1 gains within 15 minutes through IV formulation. That speed could allow rademikibart

Oppenheimer Starts Connect Biopharma Holdings Ltd (CNTB) at Outperform

Thu, 09 Jul 2026 07:47:15 -0400

(Updated - July 9, 2026 7:47 AM EDT)

Oppenheimer initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Outperform rating and a price target of $8.00.

Form 4 Connect Biopharma Holdin For: Jun 30 Filed by: Xanthopoulos Kleanthis Gabriel

Wed, 01 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260701/26721122.html

Form 4 Connect Biopharma Holdin For: Jun 30 Filed by: Xanthopoulos Kleanthis Gabriel

Wed, 01 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260701/26721122.html

Form 4 Connect Biopharma Holdin For: Jun 30 Filed by: LIU JEAN I

Wed, 01 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260701/26721110.html

Form 4 Connect Biopharma Holdin For: Jun 30 Filed by: LIU JEAN I

Wed, 01 Jul 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260701/26721110.html

Piper Sandler Starts Connect Biopharma Holdings Ltd (CNTB) at Overweight

Fri, 26 Jun 2026 03:50:39 -0400

Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Overweight rating and a price target of $7.00.

The analyst comments: “We are initiating coverage of Connect Biopharma (CNTB) with an Overweight rating and a $7 PT, based on rademikibart's differentiated mechanism, its potentially unique position as the only biologic in development for acute asthma and COPD exacerbations, and a near-term catalyst-rich setup anchored by Sept 2026 Seabreeze STAT topline data in asthma, followed shortly thereafter by the COPD readout. We believe CNTB is positioned to establish a first-mover advantage in the acute respiratory biologic

Piper Sandler Starts Connect Biopharma Holdings Ltd (CNTB) at Overweight

Fri, 26 Jun 2026 03:50:39 -0400

Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with a Overweight rating and a price target of $7.00.

H.C. Wainwright Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB)

Thu, 25 Jun 2026 06:49:49 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $7.00 price target on Connect Biopharma Holdings Ltd (NASDAQ: CNTB).

The analyst commented: "We view the AbbVie / Apogee transaction as a meaningful reminder that rademikibart’s strategic value may extend beyond the indication currently reflected in CNTB shares. CNTB remains primarily a Seabreeze acute asthma/COPD story, and we continue to believe that is the right near-term focus given the upcoming readouts and the differentiated acute exacerbation opportunity. However, the chronic respiratory opportunity and with rademikibart’s China AD data, Q4W treatment experience, and mechanistic differentiation within the IL-4Rα class make the asset

H.C. Wainwright Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB)

Thu, 18 Jun 2026 06:49:10 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $7.00 price target on Connect Biopharma Holdings Ltd (NASDAQ: CNTB).

The analyst commented: "The company also noted that enrollment in the Phase 2 Seabreeze STAT COPD study remains on track to complete this month, with COPD data expected soon after the asthma readout. We view the update as incrementally positive because it removes the remaining timing uncertainty around the most important near-term catalyst for CNTB. With Seabreeze Asthma now fully enrolled, COPD nearing completion, prior DMC review supporting continuation without a sample size increase, and cash runway into 2H27, we continue

Connect Biopharma completes enrollment in Phase 2 asthma drug study

Wed, 17 Jun 2026 09:00:24 -0400

Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study, which is evaluating rademikibart as an adjunct to standard of care for acute exacerbations in patients with asthma and type 2 inflammation.

The study enrolled 160 participants globally who experienced an acute asthma exacerbation with an eosinophil count of at least 300 cells/μL. Participants received either a single dose of rademikibart or placebo, administered subcutaneously. The primary endpoint is treatment failure rate over 28 days following an acute exacerbation, with a key secondary endpoint measuring lung function at Week 1.

The company expects

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Wed, 17 Jun 2026 09:00:00 -0400

– On track to also complete enrollment in the Seabreeze STAT COPD study this month –

– Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 –

– Strong balance sheet with cash runway into 2H 2027 –

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Wed, 17 Jun 2026 09:00:00 -0400

– On track to also complete enrollment in the Seabreeze STAT COPD study this month –

– Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 –

– Strong balance sheet with cash runway into 2H 2027 –